Researchers engineered mRNA-delivered bispecific antibodies derived from llama candidates to neutralize a range of SARS-CoV-2 variants. In mouse experiments, the approach protected against the immune-evasive XBB.1.5 Omicron subvariant. The work extends a key theme in variant-era therapeutics: combining breadth via bispecific recognition with delivery formats designed to accelerate updates when antigenic drift reshapes viral escape.